Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY4R | P50391 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL15941501 | 0.96 | PRCP (0.34) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL17889143 | 0.92 | GSR (0.34) | PRCPNPY1RNPY4R | |
| Arginine SCHEMBL15941088 | 0.92 | GSR (0.34) | PRCPNPY1RNPY4R | |
| Arginine SCHEMBL11905364 | 0.89 | PRCP (0.40) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL6369693 | 0.89 | PRCP (0.37) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL27036832 | 0.88 | PRCP (0.39) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL4398586 | 0.88 | PRCP (0.36) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL28880704 | 0.88 | PRCP (0.37) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL1840912 | 0.87 | PRCP (0.40) | PRCPNOS2NOS3NOS1OTC | |
| Arginine SCHEMBL20242303 | 0.87 | PRCP (0.40) | PRCPNOS2NOS3NOS1OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118078955-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078956-A | ELP fusion proteins for controlled and sustained release | 免疫新炉有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3452021-B1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | PHASEBIO PHARMACEUTICALS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20190218274-A1 | ELP FUSION PROTEINS FOR CONTROLLED AND SUSTAINED RELEASE | Immunoforge Co., Ltd. (KR) | 2019-07-18 | — | — | US | disclosed |
| EP-2023950-B1 | Urodilatin cancer treatment | UNIV SOUTH FLORIDA (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2023950-A2 | URODILATIN CANCER TREATMENT | University of South Florida (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007130672-A2 | URODILATIN CANCER TREATMENT | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-11-15 | — | — | WO | disclosed |